Table 3

Abomasal fluid pharmacokinetic parameters (mean ± SD, n = 4) for flubendazole (FLBZ) and its reduced metabolite (R-FLBZ) obtained after the intraruminal (i.r.) administration of FLBZ (3.8 mg/kg) formulated as a cyclodextrin-based solution (FLBZ-CDs) or a carboximethylcelullose suspension (FLBZ-CMC) to sheep (Experiment 1)
PHARMACOKINETIC PARAMETERS FLBZ R-FLBZ
FLBZ-CDs i.r. treatment FLBZ-CMC i.r. treatment FLBZ-CDs i.r. treatment FLBZ-CMC i.r. treatment
Cmax (μg/mL) 0.11 ± 0.01 0.16 ± 0.06 0.43 ± 0.13 0.67 ± 0.40*
Tmax (h) 10.5 ± 3.00 9.75 ± 2.87 12.8 ± 3.77 12.0 ± 0.00
AUC0-t (μg.h/mL) 2.95 ± 0.66 3.63 ± 1.05 12.0 ± 5.01 21.7 ± 15.8
T½el (h) 12.3 ± 5.99 9.83 ± 4.23 16.2 ± 7.54 16.3 ± 5.95
MRT (h) 23.0 ± 8.28 20.4 ± 5.23 30.0 ± 12.1 31.2 ± 8.80

T½abs/for: FLBZ absorption or metabolite formation half life; Cmax: peak plasma concentration; Tmax: time to the Cmax; AUC0-t: Area under the plasma concentration vs. time curve from 0 to the detection time; T½el: elimination half-life; MRT: mean residence time (obtained by non-compartmental analysis of the data). *Significantly different from the FLBZ-CDs i.r. treated group at P < 0.05.

Ceballos et al.

Ceballos et al. BMC Veterinary Research 2012 8:71   doi:10.1186/1746-6148-8-71

Open Data